RxDoctor Payments Data

Stephen Renae, MD

Infectious Disease · Fort Lauderdale, FLNPI 1841296670

Payments from drug & device makers

$14,478in general payments, 2019–2025

Across 545 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$6K
  • Gilead$5K
  • Johnson & Johnson$717
  • Merck$531
  • AbbVie$513
  • Insmed, Inc.$396
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$14,38899%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,478 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$498,574
Medicare patients
587
Services billed
4,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala1,137$4,290,165
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf236$1,052,660
TivicayDolutegravir Sodium411$868,889
DescovyEmtricitabine/Tenofov Alafenam391$815,358
TriumeqAbacavir/Dolutegravir/Lamivudi218$761,483
DovatoDolutegravir Sodium/Lamivudine256$761,054
PrezcobixDarunavir/Cobicistat295$678,006
GenvoyaElviteg/Cob/Emtri/Tenof Alafen155$600,485
SerostimSomatropin21$428,782
OdefseyEmtricitab/Rilpiviri/Tenof Ala115$374,329
JulucaDolutegravir/Rilpivirine26$90,940
PifeltroDoravirine46$72,638
IsentressRaltegravir Potassium39$72,208
Darunavir65$59,784
Maraviroc26$50,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$4,906$5,706,0081,683 claims
Viiv Healthcare CompanyTivicay, Triumeq, Dovato, Juluca$5,990$2,482,367911 claims
Johnson & JohnsonPrezcobix, Xarelto$717$684,923308 claims
EMD Serono, Inc.Serostim$94$428,78221 claims
MerckPifeltro, Isentress, Isentress Hd, Janumet$531$187,807124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →